Caricamento...
Pazopanib in advanced soft tissue sarcomas
Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular endothelial growth factor receptors, preclinical work indicates that pazopanib...
Salvato in:
| Pubblicato in: | Signal Transduct Target Ther |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group UK
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6522548/ https://ncbi.nlm.nih.gov/pubmed/31123606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-019-0049-6 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|